Learn More
CD262 (DR5) Monoclonal Antibody (DJR2-2 (2-6)), eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
€ 98.00 - € 234.00
Specifications
Antigen | CD262 (DR5) |
---|---|
Clone | DJR2-2 (2-6) |
Concentration | 0.5 mg/mL |
Applications | Flow Cytometry, Western Blot |
Classification | Monoclonal |
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
---|---|---|---|---|---|---|---|---|---|
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
15278227
|
Affymetrix eBioscience
14-9909-82 |
100 μg |
€ 234.00
100µg |
Estimated Shipment: 29-05-2024 Log in to see stock. |
Please sign in to purchase this item. Need a web account? Register with us today! | ||||
15268227
|
Affymetrix eBioscience
14-9909-80 |
25 μg |
This item is currently unavailable or has been discontinued. View the product page for possible alternatives. |
||||||
Description
Description: The DJR2-2 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: This DJR2-2 (a.k.a. 2-6) antibody has been reported for use in flow cytometric analysis and western blotting. Applications Tested: The DJR2-2 (a.k.a. 2-6) antibody has been tested by flow cytometric analysis of human DR5-transfected cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.Specifications
CD262 (DR5) | |
0.5 mg/mL | |
Monoclonal | |
Liquid | |
RUO | |
PBS with 0.09% sodium azide; pH 7.2 | |
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9 | |
TNFRSF10B | |
Primary | |
4° C | |
TNFRSF10B |
DJR2-2 (2-6) | |
Flow Cytometry, Western Blot | |
Unconjugated | |
Mouse | |
Human | |
O14763 | |
8795 | |
IgG1 κ | |
Affinity chromatography | |
Antibody |
For Research Use Only.